BioCentury
ARTICLE | Clinical News

ARI-3037MO: Phase I start

March 28, 2011 7:00 AM UTC

This month, Arisaph will begin a placebo-controlled, dose-escalation Phase I trial to evaluate a single dose of once-daily ARI-3037MO in about 40 healthy volunteers. Arisaph said it plans to start a m...